IHL-675A
Inflammatory Lung Conditions (e.g., ARDS, COPD)
Preclinical / Phase 1Research stage - Seeking partnership
Key Facts
Indication
Inflammatory Lung Conditions (e.g., ARDS, COPD)
Phase
Preclinical / Phase 1
Status
Research stage - Seeking partnership
Company
About Incannex Healthcare
Incannex Healthcare is a clinical-stage biotech focused on developing proprietary cannabinoid and psychedelic-based therapies for conditions with high unmet need, including sleep apnea and anxiety disorders. The company has progressed its lead asset, IHL-42X for OSA, into pivotal Phase 2/3 trials and is advancing a psilocybin program for GAD. Its strategy centers on securing intellectual property around novel formulations and treatment protocols to build a valuable clinical pipeline, funded through its dual listing on the ASX and NASDAQ.
View full company profile